1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Oxycodone (hydrochloride) |
| brand | String | OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Opioid analgesics|Opioid analgesic (semi-synthetic)]] • [[:Category:Schedule II controlled substances|Schedule II controlled substance]] • [[:Category:Analgesics|Analgesic]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' |
| starting_dose | String | IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect |
| preparations | String | IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules |
| fda_max | String | No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | 10-30 minutes (IR) |
| duration | String | 4-6 hours (IR); 12 hours (ER) |
| halflife | String | 3-5 hours (IR); 4.5 hours (ER)'"`UNIQ--ref-0000001D-QINU`"' |
| bioavailability | String | ~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"' |
| pregnancy | String | Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-0000001F-QINU`"' |
